Free shipping on all orders over $ 500


Cat. No. M3012
SKI II Structure


Size Price Availability Quantity
10mg USD 68  USD68 In stock
25mg USD 140  USD140 In stock
50mg USD 240  USD240 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

SKI II is a highly selective and non ATP-competitive S1P receptor inhibitor with IC50 of 0.5 μM, while exhibits no inhibitory on other kinases including PI3K, PKCα and ERK2.

Cell Experiment
Cell lines T-24, MCF-7, MCF-7/VP, NCI/ADR cell lines
Preparation method T24, MCF-7, MCF-7/VP, and NCI/ADR cells are plated into 96-well tissue culture plates at ~15% confluency. 24 hours Later, treating the cells are with various concentrations of inhibitors. An additional 48 hours later , cell survival is assayed using the sulforhodamine B assay
Concentrations ~50 μM
Incubation time 48 hours
Animal Experiment
Animal models JC xenografts are established in mice
Formulation DMSO (ip), polyethylene glycol 400 (oral)
Dosages ~100 mg/kg
Administration Intraperitoneal administration or oral administration
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 302.78
Formula C15H11ClN2OS
CAS Number 312636-16-1
Purity 99.36%
Solubility DMSO 50 mg/mL
Storage at -20°C

[1] Dhananjay Kumar Sah, et al. Sphingosine kinase inhibitor, SKI-II confers protection against the ionizing radiation by maintaining redox homeostasis most likely through Nrf2 signaling

[2] Corentin Claeys Bouuaert, et al. Structural and functional characterization of the Spo11 core complex

[3] Michael Hasler, et al. On the measurement of ski boot viscoelasticity

[4] Li Yang, et al. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo

[5] Ying Liu, et al. SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells

Related S1P Receptor Products
Etrasimod (APD334)

Etrasimod (APD334) is a specific and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor, with IC50 of 1.88 nM in CHO cells.

PF-543 Citrate

PF-543 Citrate is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC50 of 2 nM and a Ki of 3.6 nM.

Opaganib (ABC294640)

Opaganib (ABC294640) is a selective and competitive SK2 inhibitor with a Ki of 9.8 μM.


NIBR-0213 is an orally active, potent and S1P1-selective sphingosine 1-phosphate (S1P) receptor antagonist.


A-971432 is an orally bioavailable, non-clastogenic, azetidinecarboxylate compound that acts as a highly potent and selective sphingosine-1-phosphate receptor 5 agonist (IC50 = 6 nM/S1P5, 362 nM/S1P1 and >10 μM/S1P3 in a radio-ligand binding assay).

Abmole Inhibitor Catalog 2017

Keywords: SKI II, SphK-I2 supplier, S1P Receptor, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.